Skip to content 
On July 23, Triassic Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Triassic”), a 3D printing drug company from Nanjing, announced that it has reached a research cooperation and platform technology licensing agreement with BioNTech SE (hereinafter referred to as “BioNTech”), a next-generation immunotherapy company.
According to the agreement, the two parties will develop oral RNA drugs based on 3D printing drug technology to meet clinical needs through convenient oral formulations.
What is 3D printing drug technology? To put it simply, it is to print the API and excipients into a special structure. In cooperation with BioNTech, Triassic will give full play to the advantages of 3D printing drug technology, innovate the design of oral preparations, and optimize the delivery and absorption of RNA drugs.
RNA, or ribonucleic acid, plays an important role in transmitting genetic information in living organisms.
Triassic is able to create unique external and internal structures for drug formulations, thereby optimizing the delivery of innovative RNA drugs. The embodiment of “optimization” is that the degradation of “printed” drugs in the gastrointestinal tract is greatly reduced, and the potential optimal absorption site of the gastrointestinal tract is maximized.
Under the terms of the agreement, Triassic will receive an upfront payment of US$10 million and is expected to receive product development, registration and commercialization milestone payments totaling more than US$1.2 billion, as well as potential future tiered sales royalties.
About BioNTech SE:
BioNTech from Germany is a next-generation immunotherapy research and development company founded in 2008 and focuses on the development and production of immunotherapies for cancer, infectious diseases and other diseases.
The company is best known for partnering with Pfizer to develop the first COVID-19 mRNA vaccine approved for emergency use, demonstrating leadership in mRNA technology and breaking several world records since its launch.
About Triassic
Triassic is a 9-year-old technology platform company located in Jiangning High-tech Zone, Nanjing.
Triassic has created a number of “global firsts” in the field of 3D printed drugs. It has more than 233 patent applications, accounting for more than 20% of the global 3D printing drug field, becoming the company with the most complete patent layout and the largest number of applications in this field, and has 5 products in China and the United States with 7 IND approvals, ranking first in the global 3D printing drug field.
Previously, the World Economic Forum announced the “2024 Technology Pioneer List”, and Nanjing Triassic Pharmaceutical Technology Co., Ltd. successfully ranked among the top 100 in the world by virtue of its outstanding innovation and leading advantages in the field of 3D printing drugs.
The list brings together 100 top companies from 23 countries, of which 11 Chinese companies stand out, and Triassic is the only one in Nanjing along with two other Jiangsu companies.
In the laboratory of Triassic Pharmaceutical Technology Co., Ltd., the 3D printing drug equipment developed by the company is printing drugs. The company has built a continuous 3D printing drug production center that meets GMP standards, and the first continuous production line has an annual production capacity of 75 million tablets.
Dr. Cheng Senping, founder and CEO of Triassic, introduced that Triassic has developed the world’s first MED®3D printing drug R&D equipment, which produces and manufactures three-dimensional entities through “layered printing and layer-by-layer superposition” to freely construct the internal 3D microstructure of drugs. This 3D microstructure can control the release behavior of the drug, and according to the differences in the release and absorption of the drug in different parts of the gastrointestinal tract, the drug is precisely delivered to a specific site, so that the drug is released at the right time and place after entering the body.
At present, Triassic has a number of drug development technology platforms to meet different treatment needs, such as the 3D microstructure gastric retention platform can help patients take drugs from 3 times a day to 1 time a week, which meets the needs of people who are difficult to take drugs and people who are inconvenient to take drugs.
